<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Chem Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Chem Soc</journal-id><journal-id journal-id-type="publisher-id">ja</journal-id><journal-id journal-id-type="coden">jacsat</journal-id><journal-title-group><journal-title>Journal of the American Chemical Society</journal-title></journal-title-group><issn pub-type="ppub">0002-7863</issn><issn pub-type="epub">1520-5126</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">10996006</article-id><article-id pub-id-type="pmid">38513269</article-id>
<article-id pub-id-type="doi">10.1021/jacs.3c13208</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>The
Peptide Antibiotic Corramycin Adopts a &#x003b2;-Hairpin-like
Structure and Is Inactivated by the Kinase ComG</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Adam</surname><given-names>Sebastian</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-1" ref-type="notes">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Fries</surname><given-names>Franziska</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x025cb;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="notes-1" ref-type="notes">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>von Tesmar</surname><given-names>Alexander</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-1" ref-type="notes">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Rasheed</surname><given-names>Sari</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Deckarm</surname><given-names>Selina</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6735-3455</contrib-id><name><surname>Sousa</surname><given-names>Carla F.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Reber&#x00161;ek</surname><given-names>Roman</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath8"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-2212-8232</contrib-id><name><surname>Risch</surname><given-names>Timo</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x025cb;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Mancini</surname><given-names>Stefano</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath10"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3398-9938</contrib-id><name><surname>Herrmann</surname><given-names>Jennifer</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Koehnke</surname><given-names>Jesko</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Kalinina</surname><given-names>Olga V.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff6" ref-type="aff">#</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath13"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1042-5665</contrib-id><name><surname>M&#x000fc;ller</surname><given-names>Rolf</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x025cb;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre
for Infection Research (HZI), <institution>Saarland University</institution>, Campus E8 1, 66123 Saarbr&#x000fc;cken, <country>Germany</country></aff><aff id="aff2"><label>&#x025cb;</label>Department
of Pharmacy, <institution>Saarland University</institution>, 66123 Saarbr&#x000fc;cken, <country>Germany</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>German
Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig</institution>, 38124 Braunschweig, <country>Germany</country></aff><aff id="aff4"><label>&#x02225;</label>Institute
of Medical Microbiology, <institution>University of Z&#x000fc;rich</institution>, 8006 Z&#x000fc;rich, <country>Switzerland</country></aff><aff id="aff5"><label>&#x022a5;</label>Institute
of Food Chemistry, <institution>Leibniz University Hannover</institution>, Callinstra&#x000df;e 5, 30167 Hannover, <country>Germany</country></aff><aff id="aff6"><label>#</label>Faculty of
Medicine, <institution>Saarland University</institution>, 66421 Homburg , <country>Germany</country></aff><aff id="aff7"><label>g</label>Center for
Bioinformatics, <institution>Saarland University</institution>, 66123 Saarbr&#x000fc;cken, <country>Germany</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>rolf.mueller@helmholtz-hips.de</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>03</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>03</day><month>04</month><year>2024</year></pub-date><volume>146</volume><issue>13</issue><fpage>8981</fpage><lpage>8990</lpage><history><date date-type="received"><day>24</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>04</day><month>03</month><year>2024</year></date><date date-type="rev-recd"><day>01</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0007" id="ab-tgr1"/></p><p>The rapid development
of antibiotic resistance, especially among
difficult-to-treat Gram-negative bacteria, is recognized as a serious
and urgent threat to public health. The detection and characterization
of novel resistance mechanisms are essential to better predict the
spread and evolution of antibiotic resistance. Corramycin is a novel
and modified peptidic antibiotic with activity against several Gram-negative
pathogens. We demonstrate that the kinase ComG, part of the corramycin
biosynthetic gene cluster, phosphorylates and thereby inactivates
corramycin, leading to the resistance of the host. Remarkably, we
found that the closest structural homologues of ComG are aminoglycoside
phosphotransferases; however, ComG shows no activity toward this class
of antibiotics. The crystal structure of ComG in complex with corramycin
reveals that corramycin adopts a &#x003b2;-hairpin-like structure and
allowed us to define the changes leading to a switch in substrate
from sugar to peptide. Bioinformatic analyses suggest a limited occurrence
of ComG-like proteins, which along with the absence of cross-resistance
to clinically used drugs positions corramycin as an attractive antibiotic
for further development.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>Deutsches Zentrum f&#x000c3;&#x00083;&#x000c2;&#x000bc;r Infektionsforschung</institution><institution-id institution-id-type="doi">10.13039/100009139</institution-id></institution-wrap></funding-source><award-id>8004809827</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>European Commission</institution><institution-id institution-id-type="doi">10.13039/100010663</institution-id></institution-wrap></funding-source><award-id>101002326</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ja3c13208</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ja3c13208</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The spread of antimicrobial resistance
(AMR) represents one of
the principal public health problems of this century and has consequently
been declared as one of the top 10 global public health threats by
the World Health Organization (WHO) in 2019.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> Infections
with Gram-negative bacteria, in particular those included in the list
of ESKAPE (<italic>Enterococcus faecium</italic>, <italic>Staphylococcus
aureus</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Acinetobacter
baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Enterobacter</italic> spp.) pathogens, are a major concern due to
their tendency to acquire multidrug resistance.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> Research
efforts have thus largely focused on the development of new bioactive
compounds against Gram-negative bacteria, ideally addressing innovative
targets.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup></p><p>The investigation of the specialized
metabolism of myxobacteria,
&#x003b4;-proteobacteria known for their complex life cycle and social
behavior, has resulted in the isolation of natural products exhibiting
high chemical diversity and unusual modes of action.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup><italic>Corallococcus coralloides</italic> species are
the producers of the natural products corramycins, which were isolated
in an activity-guided isolation process aiming to identify novel chemical
scaffolds exhibiting activity against Gram-negative pathogens. Corramycins
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A) are linear,
peptidic natural products harboring several modified amino acids as
well as an N-terminal butyric acid and a thus far undescribed &#x003b3;-<italic>N</italic>-methyl-&#x003b2;-OH-histidine.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup> The biosynthetic
gene cluster (BGC) responsible for the production of corramycins was
identified as a 12-modular hybrid nonribosomal peptide synthetase
(NRPS)&#x02013;polyketide synthase (PKS) megasynthetase assembly line
organized in one operon (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B). The major product of this BGC exhibited substantial
antimicrobial activity against different Gram-negative bacteria (e<italic>.</italic>g., minimum inhibitory concentration (MIC) against <italic>Escherichia coli</italic> NCTC13441 = 4 &#x003bc;g mL<sup>&#x02013;1</sup>) and was active in a first <italic>in vivo</italic> proof of concept
study in rodents.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> A hydroxylated derivative
and a derivative with additional glycosylation were isolated as side
products (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A).
The mode of action of corramycins is still elusive, but given their
potency and spectrum, we investigated how the producing organism had
established self-resistance and whether the underlying resistance
mechanism is already present among bacteria.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(A) Chemical structure
of corramycins. (B) Representation of the
biosynthetic gene cluster (BGC) of corramycins. Biosynthetic genes
are colored based on their function. (C) Chemical structures of tobramycin
(left panel) and gentamicin C<sub>1</sub> (right panel). NRPS: nonribosomal
peptide synthetase; PKS: polyketide synthase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0001" id="gr1" position="float"/></fig><p>Genes related to self-resistance mechanisms being
directly linked
to the BGC encoding the biosynthesis is a common feature of microbial
natural product production.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> This fact
has even been exploited in the search for new natural products in
the so-called self-resistance-guided genome mining.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> The understanding of the underlying mechanisms of bacterial
resistance against antibiotics as well as their epidemiological distribution
is vital to develop successful counterstrategies as early as possible
in the drug development process. In general, the most common mechanisms
of AMR by prokaryotes include enzymatic inactivation, target modification,
porin defects, and overexpression of efflux transporters.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup></p><p>Aminoglycosides, such as tobramycin and gentamicin (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C), are antibiotics
of high
clinical relevance due to their bactericidal activity and broad-spectrum
profiles. Aminoglycoside phosphotransferases (APHs), which phosphorylate
specific hydroxyl groups in aminoglycosides, are very effective inactivators
of this class of antibiotics.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> Although other resistance
mechanisms against aminoglycosides can occur, the synthesis of aminoglycoside-modifying
enzymes (AMEs) is the predominant mode of resistance in clinical isolates.
The evolutionary success of AMEs is attributed to the ability of most
enzymes to act on more than one aminoglycoside in addition to their
frequent occurrence on mobile genetic elements, increasing their likelihood
of dissemination among species.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Intriguingly,
there have been scarce reports of enzymes with a substrate range beyond
the aminoglycosides such as the kinase Cph, which confers self-resistance
to the peptide-based antibiotic capreomycin.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Capreomycin, viomycin, and derivatives thereof constitute the antibiotic
class of tuberactinomycins, which represent effective treatments against
multidrug-resistant tuberculosis (MDR TB).<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> In another case, there are reports of low-level resistance to the
structurally very different class of fluoroquinolones conferred by
the acetylation of ciprofloxacin and norfloxacin by an enzyme related
to an APH.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> Consequently, there have been
hypotheses that aminoglycoside phosphotransferases and common kinases
evolved from a mutual ancestor and share a general kinase fold and
kinetic mechanism.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></p><p>Herein, we describe
the kinase ComG from the corramycin BGC as
a self-resistance factor of <italic>C. coralloides</italic>. We demonstrate
that the expression of ComG leads to resistance in <italic>E. coli</italic>. The reconstitution of the ComG activity <italic>in vitro</italic> allowed us to pinpoint the position of phosphorylation on the corramycin
backbone. The crystal structure of ComG in complex with corramycin
revealed an unexpected &#x003b2;-hairpin-like conformation of the natural
product and shed light on the catalytic mechanism. Importantly, ComG-like
enzymes were not found widely distributed among bacteria, and related
aminoglycoside-modifying enzymes do not confer resistance to corramycin,
indicating little pre-existing resistance and, thus, showing great
potential for corramycin to be developed as a novel class of antibiotics.</p></sec><sec id="sec2"><title>Results
and Discussion</title><sec id="sec2.1"><title>The Corramycin BGC Contains a Gene Related
to Aminoglycoside
Kinases</title><p>The corramycin BGC contains 15 genes, most of which
belong to the modular hybrid PKS/NRPS assembly line and the corresponding
tailoring genes for the biosynthesis of the natural product (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B). In the search
for a characteristic self-resistance gene, we expressed several potential
tailoring genes in <italic>E. coli</italic> and found <italic>comG</italic> to confer corramycin resistance (MIC 256 &#x003bc;g mL<sup>&#x02013;1</sup>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S1</ext-link>).</p><p>A search of the nonredundant
protein sequences database using blastP and ComG as a query revealed
that its closest homologues are kinases conferring resistance to aminoglycoside
antibiotics. We did not observe any shift in the inhibitory concentration
of reference antibiotics, including aminoglycosides, for ComG-expressing <italic>E. coli</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S1</ext-link>). Thus, ComG
cannot confer resistance to members of this antibiotic class, suggesting
rather poor structural homology between the substrate binding site
of ComG and those of other aminoglycoside kinases. Based on this finding,
we were intrigued to understand how the peptidic antibiotic corramycin
may be bound and modified by ComG.</p></sec><sec id="sec2.2"><title>ComG Phosphorylates Corramycin
in an Unprecedented Position</title><p>After we observed that ComG
conferred resistance to <italic>E.
coli</italic>, we attempted to reconstitute this activity <italic>in vitro</italic>. The enzyme was expressed in <italic>E. coli</italic> Lemo21 (DE3) and purified to homogeneity (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S2A</ext-link>), and analysis of ComG using intact protein mass spectrometry
showed very good agreement between observed and calculated mass (<italic>m</italic><sub>obs</sub> = 40,949.37 Da, <italic>m</italic><sub>calc</sub> = 40,949.97 Da, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S2B</ext-link>). Upon incubation
of corramycin with ComG in the presence of ATP and MgCl<sub>2</sub> at 22 &#x000b0;C, we observed a mass shift of +79.97 Da, corresponding
to the addition of a phosphate group (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). As expected, no substrate conversion
was observed without the addition of ATP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S3</ext-link>). Interestingly, ComG heavily favors ATP over GTP as the
phosphate donor for its catalytic function (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S4</ext-link>), which is in contrast to the capreomycin kinase Cph, which
shows comparable conversion for both nucleotides.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> In addition, the enzyme kinetics for the reaction of ComG
with ATP were analyzed for a series of corramycin concentrations,
and <italic>K</italic><sub>m</sub> and <italic>k</italic><sub>cat</sub> values were determined to be 33 &#x003bc;M and 1 min<sup>&#x02013;1</sup>, respectively (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S5</ext-link>).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>ComG phosphorylates
corramycin in an unprecedented position. (A)
HR-LCMS analysis of an <italic>in vitro</italic> reaction of corramycin
with ComG and ATP/MgCl<sub>2</sub>. Extracted ion chromatograms (EIC)
show a characteristic mass shift of +80 Da, hinting at the addition
of a phosphate group (left panel: + ATP/&#x02013; ComG; right panel:
+ ComG/ATP). The negative control depicting the reaction of corramycin
with ComG, but without ATP, can be found in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S3</ext-link>. (B) Tandem MS/MS analysis of the product of the ComG reaction
Cor-P (phosphorylated corramycin). Characteristic shifts of y8 and
b3 ions highlight the position of phosphorylation being the &#x003b2;-alanine
moiety. Full mass tables of corramycin and Cor-P fragmentation by
MS/MS analysis are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Tables S2 and S3</ext-link>. NMR data of Cor-P can be found in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S7</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0002" id="gr2" position="float"/></fig><p>We hypothesized that the phosphorylation
of corramycins may be
the inactivation mechanism inside living cells. To support this hypothesis,
the inhibitory concentration of the purified, phosphorylated corramycin
(Cor-P) against <italic>E. coli</italic> was determined. Cor-P showed
no antibacterial activity (inhibitory concentration &#x0003e;64 &#x003bc;g
mL<sup>&#x02013;1</sup>), confirming the inactivation of corramycin
via phosphorylation
by ComG. To identify the site of phosphorylation, we analyzed Cor-P
using tandem mass spectrometry (MS<sup>2</sup>) and nuclear magnetic
resonance (NMR). MS<sup>2</sup> of Cor-P confirmed a mass shift of
+80 Da and placed the mass shift on the characteristic b3 and y8 ions
(<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>B and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">S6, Tables S2 and S3</ext-link>). Superposition of the HMBC
NMR spectra of corramycin and Cor-P showed characteristic <sup>1</sup>H- and <sup>13</sup>C-shifts of 0.3 ppm and approximately 3 ppm,
respectively, for the C<sub>3</sub> atom of the &#x003b2;-alanine incorporated
by the PKS of the BGC. These data agree with the site of modification
as determined by MS<sup>2</sup> and allowed us to pinpoint the specific
atom that is phosphorylated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S7</ext-link>).</p></sec><sec id="sec2.3"><title>Overall Structural Analysis of ComG</title><p>Aminoglycoside
kinases have been the subject of intense research due to their involvement
in AMR against an important clinical class of antibiotics. As aminoglycosides
and the linear peptide corramycin do not share obvious chemical or
structural space, we were intrigued by the idea of obtaining structural
information on ComG. Low sequence identity to published aminoglycoside
phosphotransferase protein structures required us to produce ComG
in which methionine had been replaced by selenomethionine for experimental
phasing. This protein crystallized in space group <italic>P</italic>2<sub>1</sub>, and a data set was collected to a resolution of 2.1
&#x000c5;. The structure was determined using single-wavelength anomalous
dispersion (all data collection and refinement statistics can be found
in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S4</ext-link>). The presence of translational
pseudosymmetry complicated refinement of the structure.</p><p>Apo
ComG contained two protomers in the asymmetric unit, and the refined
model encompassed residues 14&#x02013;33, 39&#x02013;57, and 66&#x02013;364
for chain A (13&#x02013;33, 40&#x02013;56, and 66&#x02013;364 for chain
B). The enzyme adopts the typical bilobed kinase fold, with the N-terminal
lobe being formed primarily by &#x003b2;-sheets, while the C-terminal
lobe consists predominantly of &#x003b1;-helices (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A). The ATP-binding hinge region is found
in the loop between the two lobes, with the conserved glycine residue
leading to the parallel orientation of the backbone, which in turn
is expected to coordinate the adenine of ATP. On the opposing side
of the hinge region lies the &#x0201c;DFG loop&#x0201d;, which in ComG
is mutated to a DFE motif (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S8</ext-link>).
The conserved aspartate residue is critical for the coordination of
the magnesium cation and, thus, for the orientation of the phosphate
region of ATP. The surface representation of ComG revealed a wide
pocket between the N- and C-terminal lobes that appeared suitable
to accommodate a larger natural product (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). In addition, residues on both sides of
the pocket extending toward the solvent could possibly act as a closing
lid above both the substrate and cofactor binding sites.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(A) Cartoon
representation of the crystal structure of apo ComG,
highlighting the typical bilobed kinase fold. The N-terminal lobe
is shown in blue, the hinge region in green, and the C-terminal lobe
in orange. (B) Surface representation of the crystal structure of
apo ComG, with the same color coding as that in A. (C) Surface representation
of ComG<sup>C</sup>. Protein residues are shown in pale green, whereas
corramycin is shown as yellow sticks. (D) Structure of corramycin
bound to ComG adopts a &#x003b2;-hairpin-like structure. The hydroxyl
group that is phosphorylated by ComG is marked with an asterisk.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0003" id="gr3" position="float"/></fig><p>A search for structural homologues of ComG using
the DALI server
revealed an uncharacterized kinase (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="3csv">3csv</ext-link>) as the closest hit with a C<sub>&#x003b1;</sub> RMSD of 4.0 &#x000c5; and 79% sequence coverage. The closest structural
homologue for which the structure had been determined with a bound
substrate was aminoglycoside 7&#x02033;-phosphotransferase-Ia, which
phosphorylates and thereby inactivates the aminoglycoside antibiotic
hygromycin B (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="6IY9">6IY9</ext-link>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S9</ext-link>). The overall structural
homology is fair, with a C<sub>&#x003b1;</sub> RMSD of 3.73 &#x000c5;,
but only just over half of the C<sub>&#x003b1;</sub> atoms could be
aligned structurally (52%). The poor structural homology was somewhat
expected, since ComG acts on a peptidic substrate and led us to pursue
crystallization of the ComG&#x02013;corramycin complex.</p></sec><sec id="sec2.4"><title>Corramycin
Adopts a &#x003b2;-Hairpin-like Structure</title><p>To this end, ComG
was incubated with a 5-fold molar excess of corramycin,
a 10-fold molar excess of the nonhydrolyzable ATP analogue AMPPCP,
and MgCl<sub>2</sub> for 24 h at 4 &#x000b0;C before crystallization
trials were attempted. ComG complex crystals (ComG<sup>C</sup>) were
observed in multiple conditions and also belonged to space group <italic>P</italic>2<sub>1</sub>, and a data set was processed to a resolution
of 1.5 &#x000c5;. The structure of ComG<sup>C</sup> was determined by
molecular replacement using the ComG structure as a search model.
Interestingly, the addition of corramycin led to a significant difference
in crystal packing, as ComG<sup>C</sup> only had a single protomer
in the asymmetric unit, and the pathology observed for ComG crystals
was no longer present. Binding of corramycin did not lead to notable
movement in the structure of ComG when comparing apo and complex structures
(C<sub>&#x003b1;</sub> RMSD of 0.35 &#x000c5;), with the exception of the
loop connecting residues 33 and 39, which is ordered in the ComG<sup>C</sup> structure. This is likely a direct result of a hydrogen bond
between corramycin and Arg38 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S10</ext-link>).</p><p>We observed unambiguous electron density for corramycin
in a pocket formed between the N- and C-terminal lobes but could not
observe any density for AMPPCP/Mg<sup>2+</sup> (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>C and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">S10</ext-link>). Unexpectedly,
the three-dimensional structure of corramycin was reminiscent of two
antiparallel &#x003b2;-strands, which adopt a &#x003b2;-hairpin-like structure
that is stabilized by six intramolecular hydrogen bonds (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>D and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">S11</ext-link>). The turn of the hairpin is composed of
the <italic>N</italic>-methyl-phenylalanine, the side chain of which
is bound in a hydrophobic pocket, and part of the hydroxylated &#x003b3;-amino
valeroyl moiety, which is also the site of corramycin phosphorylation
by ComG. This region of corramycin is further stabilized by two hydrogen
bonds between the natural product and ComG (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S12</ext-link>). Interestingly, the position of this moiety at the turn,
the site of phosphorylation, leads to a conformation that could be
viewed as mimicking a hexose (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>D), with both hydroxyl groups pointing toward the putative
ATP-binding site.</p><p>Structures of APH-related enzymes in complex
with peptide-based
natural products have been reported only once, for the capreomycin
kinase Cph.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Even though the bilobed architecture
of both enzymes is somewhat similar, the overall structural homology
is low (C<sub>&#x003b1;</sub> RMSD of 6.22 &#x000c5;) and, thus, even lower
than the homology to the more unrelated APHs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S13</ext-link>). The biggest structural differences are the absence
of two C-terminal ComG loops and one &#x003b1;-helix (residues 285&#x02013;315
and 345&#x02013;364) in Cph, which are crucial for the formation of
the hydrophobic pocket and, therefore, for corramycin binding. In
contrast, the characteristic macrocycle of capreomycin is extending
into the helical architecture of the C-terminal lobe, leading to the
compound adopting a &#x0201c;C&#x0201d; shape.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Intriguingly, this conformation is also the result of multiple intramolecular
hydrogen bonds. Somewhat expected based on these results, we were
unable to detect any phosphorylation of capreomycin by ComG, which
highlights the structural differences of the substrate binding pocket
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S14 and Table S1</ext-link>).</p></sec><sec id="sec2.5"><title>Modeling of
the Catalytic Center</title><p>Despite adding a 10-fold
molar excess of AMPPCP/MgCl<sub>2</sub>, we did not observe convincing
electron density for the ATP analogue in the complex structure. This
may be due to a rather mediocre affinity or the fact that corramycin
binding in the active site with a high affinity occluded AMPPCP from
the pocket during the crystallization process. To better understand
the catalytic mechanism, we set out to model ATP into our complex
structure using molecular dynamics (MD) simulations. As an initial
step, one ATP and one Mg<sup>2+</sup> were placed at the presumed
ATP-binding site of ComG (hinge region, DFE motif). Next, the system
was minimized, equilibrated, and simulated for 100 ns. In our simulations,
the adenine group of ATP established an H-bond with the backbone carbonyl
oxygen of Leu100 from the hinge region (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S15</ext-link>). The Mg<sup>2+</sup> center is hexacoordinated with an
octahedral geometry, the most usual coordination for Mg<sup>2+</sup> in biological macromolecules,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> which
was previously described for an aminoglycoside kinase.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> According to our simulations, Mg<sup>2+</sup> is coordinated by two oxygens of the side chains of Asp220 and Glu222
from the DFE loop of ComG and by the triphosphate group of ATP (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). Despite ATP acting
as a ligand in both of the simulations, in one of them, it acted as
a tridentate ligand (production 1) and in the other as a bidentate
ligand (production 2, <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). The coordination with Glu222 is very stable and was observed
in both of our simulations; Asp220, however, acted as a ligand in
only one of our simulations (production 1, <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>D).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Mg<sup>2+</sup> coordination center. (A, B)
Representation of the
coordination center in production 1 (A) and production 2 (B). Mg<sup>2+</sup> is shown in dark green, DFE residues and water are shown
with balls and sticks, and ATP is shown with sticks. Carbon atoms
are colored in yellow, nitrogen in blue, oxygen in red, phosphorus
in gold, and hydrogens in white. Protein backbone is shown in pale
green. (C, D) Distance between the Mg<sup>2+</sup> center and the
oxygen ligands from ATP (C) and from Asp220 or Glu222 (D). Results
from production 1 are shown with solid lines, and results from production
2 are shown with dashed lines. Oxygens from ATP are labeled as shown
in the representation on the upper left side of C.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0004" id="gr4" position="float"/></fig><p>Furthermore, we analyzed the cofactor binding preferences
of ComG
by comparing the modeled ATP pose to that of bound nucleotides in
other APHs (Pfam family PF01636, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S6</ext-link>). Although sequence conservation in this family is low, the amino
acid pattern in ComG indicates a larger similarity to the ATP binding
pocket in other kinases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S16</ext-link>).</p><p>The role of the water molecules in the coordination of the Mg<sup>2+</sup> center is also important, at least as a transient ligand.
In fact, in one of our simulations (production 2), Mg<sup>2+</sup> is coordinated with three water molecules for the full 100 ns of
our simulation (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B). Furthermore, the orientation of the N-terminal chain of corramycin
also seems to be important for its interaction with ATP, as depicted
in the comparison between the position of corramycin after 90 ns of
simulation in productions 1 and 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S17</ext-link>). We also followed the distance between the oxygen of the C<sub>3</sub>-hydroxyl group derived from the carboxy group of &#x003b2;-alanine
from corramycin and the terminal phosphate from ATP along the simulated
time (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S18</ext-link>), and all simulation data
agree with experimental observation.</p></sec><sec id="sec2.6"><title>Bioinformatic Analysis
and Evolution of ComG</title><p>Naturally
occurring resistance is a major concern in the exploration of novel
potential antibiotics. We thus performed a thorough bioinformatic
analysis to explore the evolutionary spread of potential resistance
mediated by ComG-like proteins through genome mining in the order <italic>Myxococcales</italic> and the phylum <italic>Actinobacteria</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S19</ext-link>). In the <italic>Myxococcales</italic>, we only found one homologue with high sequence identity on the
protein level (72.5%, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S1</ext-link>) in three
identical NRPS/T1PKS-type clusters in <italic>Myxococcus llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogochensis</italic>, <italic>Myxococcus guangdongensis</italic>, and <italic>Myxococcus</italic> sp. CA040A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S19</ext-link>). In <italic>Actinobacteria</italic>, we found several homologues with a relatively low sequence identity
(25&#x02013;30%) but good coverage (sequence similarity observed over
&#x0003e;75% of the entire ComG length) in BGCs of very different types,
ranging
from aryl polyene to NRPS and siderophores. These data may indicate
other instances in which aminoglycoside-like phosphotransferases acquired
a substrate range that is broader than aminoglycoside antibiotics,
but experimental verification will be required before firm conclusions
can be drawn.</p><p>Our bioinformatic analysis, along with the structural
data presented above, supports the notion that aminoglycoside-like
kinases are branched in the kinase protein family and share an evolutionary
origin as well as catalytic mechanisms with other kinases.</p><p>In
order to further characterize potential pre-existing corramycin
resistance in bacteria, we explored the phylogenetic spread of ComG-like
enzymes, irrespective of their position in BGCs. ComG belongs to the
phosphotransferase enzyme family APH (Pfam family PF01636). However,
this domain does not extend to the C-terminal region of the protein,
comprising positions 285&#x02013;315 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A), which is crucial for corramycin binding.
Thus, most proteins in this family are likely incapable of binding
corramycin.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>(A) Cartoon structure of ComG. The C-terminal corramycin-binding
region between Trp285 and Tyr315 is colored orange, whereas the natural
product is shown as violet sticks. (B) Phylogenetic tree of ComG-like
proteins with a conserved C-terminal corramycin-binding region. Branches
corresponding to important taxa are shown in color. ComG is shown
in gold. (C) Sequence logo of conservation of corramycin-binding residues.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0005" id="gr5" position="float"/></fig><p>To narrow down the potential set of corramycin-binding
APHs, we
searched for homologues of ComG with BLAST and filtered them in such
a way that the sequence similarity extended into the corramycin-binding
C-terminal region. This yielded 202 proteins, predominantly phosphotransferases
from <italic>Myxococcota</italic> and <italic>Actinomycetota</italic> and kinases and hypothetical proteins in other phyla from the <italic>Terrabacteria</italic> group such as <italic>Armatimonada</italic>, <italic>Bacillota</italic>, <italic>Cyanobacteriota</italic>, and <italic>Chloroflexota</italic>, as well as from a candidate
phylum <italic>Rokubacteria</italic>. The corramycin kinase lies on
a branch separated from other myxobacteria, with four proteins from <italic>Myxococcus</italic> sp. CA040A, <italic>M. llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogochensis</italic>, and <italic>M. guangdongensis</italic> that are annotated as phosphotransferases
or aminoglycoside phosphotransferase family proteins. In these species,
the ComG homologue is embedded in a BGC that is very similar to the
corramycin BGC. A distant branch corresponds to GNAT family <italic>N</italic>-acetyltransferases from <italic>Legionella</italic> spp.
and several other closely related proteins from <italic>Pseudomonadota</italic> (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B). Analysis
of conservation of corramycin-binding residues in these proteins shows
a reasonable conservation within the phosphotransferase domain but
a severe drop of conservation in the corramycin-binding C-terminal
region, spanning positions 285&#x02013;315 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>C). Structural analysis shows that this region
is crucial for binding of corramycin. These data indicate that ComG
is a distinct kinase with very few homologues in the kingdom of bacteria.</p><p>In order to identify potential naturally occurring resistance in
pathogenic bacteria, we searched the CARD database (Comprehensive
Antibiotic Resistance Database<sup><xref ref-type="bibr" rid="ref23">23</xref></sup>) for homologues
of ComG, but in none of these hits did homology expand to the corramycin-binding
C-terminal part. Together with an overall low homology, we propose
that these proteins do not confer corramycin resistance. When we further
analyzed the ESKAPE pathogens, we found five hits that were deemed
significant and fell within the CARD branch of the phylogenetic tree
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B). Based
on their taxonomic diversity, three genes were cloned, expressed in <italic>E. coli</italic> BL21 (DE3) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Figure S20</ext-link>), and tested for their activity toward corramycin. As expected and
unlike ComG, we observed no MIC shift for the three tested ComG homologues,
and they thus do not confer resistance to corramycin (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S7</ext-link>).</p></sec><sec id="sec2.7"><title>Corramycin Overcomes Aminoglycoside
Resistance Mediated through
AMEs</title><p>Given the relation of ComG to aminoglycoside phosphotransferases,
we aimed to investigate a potential cross-resistance to this class
of antibiotics. To this end, we assessed the antibacterial activity
of corramycin against 57 <italic>E. coli</italic> clinical isolates,
55 of which express different classes and combinations of AMEs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S8</ext-link>).<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Corramycin
MICs were distributed unimodally with an MIC<sub>50</sub> of 8 &#x003bc;g
mL<sup>&#x02013;1</sup> and MIC<sub>90</sub> of 16 &#x003bc;g mL<sup>&#x02013;1</sup> (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Besides
imipenem and colistin, corramycin was the only antibiotic that remained
active, irrespective of the resistance mechanism, indicating that
the peptide is not inactivated by AMEs nor is it affected by other
antimicrobial resistance determinants conferring resistance to antibiotics
like fluoroquinolones, tetracyclines, or trimethoprim.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>MIC<sub>50</sub> and MIC<sub>90</sub> of Corramycin and Reference
Antibiotics among 57 Multidrug-Resistant <italic>Escherichia coli</italic> Clinical Isolates<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th colspan="3" align="center">MIC
[&#x003bc;g mL<sup>&#x02013;1</sup>]<hr/></th></tr><tr><th style="border:none;" align="center">antibiotic</th><th style="border:none;" align="center">EUCAST CBP<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> [&#x003bc;g&#x000a0;mL<sup>&#x02013;1</sup>]</th><th style="border:none;" align="center">MIC range (<italic>n</italic>&#x000a0;=&#x000a0;57)</th><th style="border:none;" align="center" char=".">MIC<sub>50</sub></th><th style="border:none;" align="center" char=".">MIC<sub>90</sub></th></tr></thead><tbody><tr><td style="border:none;" align="left">corramycin</td><td style="border:none;" align="left">n/a</td><td style="border:none;" align="left">2 to &#x0003e;64</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">16</td></tr><tr><td style="border:none;" align="left">amikacin</td><td style="border:none;" align="left">8</td><td style="border:none;" align="left">4 to 64</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">32</td></tr><tr><td style="border:none;" align="left">gentamicin<xref rid="t1fn1" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">2 to &#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td></tr><tr><td style="border:none;" align="left">kanamycin<xref rid="t1fn2" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">n/a</td><td style="border:none;" align="left">4 to &#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td></tr><tr><td style="border:none;" align="left">neomycin<xref rid="t1fn3" ref-type="table-fn">d</xref></td><td style="border:none;" align="left">n/a</td><td style="border:none;" align="left">2 to &#x0003e;64</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">&#x0003e;64</td></tr><tr><td style="border:none;" align="left">tobramycin</td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">2 to &#x0003e;64</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">&#x0003e;64</td></tr><tr><td style="border:none;" align="left">imipenem</td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">0.25&#x000a0;to&#x000a0;2</td><td style="border:none;" align="char" char=".">0.5</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">colistin</td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">0.25 to 0.5</td><td style="border:none;" align="char" char=".">0.5</td><td style="border:none;" align="char" char=".">0.5</td></tr><tr><td style="border:none;" align="left">ciprofloxacin</td><td style="border:none;" align="left">0.25<xref rid="t1fn4" ref-type="table-fn">e</xref></td><td style="border:none;" align="left">0.016 to &#x0003e;8</td><td style="border:none;" align="char" char=".">&#x0003e;8</td><td style="border:none;" align="char" char=".">&#x0003e;8</td></tr><tr><td style="border:none;" align="left">levofloxacin</td><td style="border:none;" align="left">0.5</td><td style="border:none;" align="left">0.03 to &#x0003e;16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">&#x0003e;16</td></tr><tr><td style="border:none;" align="left">tetracycline</td><td style="border:none;" align="left">n/a</td><td style="border:none;" align="left">2 to &#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td></tr><tr><td style="border:none;" align="left">trimethoprim</td><td style="border:none;" align="left">4<xref rid="t1fn5" ref-type="table-fn">f</xref></td><td style="border:none;" align="left">0.5 to &#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td><td style="border:none;" align="char" char=".">&#x0003e;64</td></tr></tbody></table><table-wrap-foot><fn id="tbl1-fn1"><label>a</label><p>Minimum inhibitory concentrations
(MICs) were determined in cation-adjusted Mueller-Hinton broth (MHB2)
using the broth microdilution method according to the EUCAST guidelines.
Values represent two independent repeats. CBP: clinical breakpoint;
EUCAST: European Committee on Antimicrobial Susceptibility Testing;
n/a: not available.</p></fn><fn id="t1fn1"><label>b</label><p>Combination
of gentamicin C<sub>1</sub>, C<sub>1a</sub>, and C<sub>2</sub>.</p></fn><fn id="t1fn2"><label>c</label><p>Main component kanamycin A.</p></fn><fn id="t1fn3"><label>d</label><p>Main component neomycin B.</p></fn><fn id="t1fn4"><label>e</label><p>Indications other than meningitis.</p></fn><fn id="t1fn5"><label>f</label><p>Uncomplicated urinary tract
infections
(UTI).</p></fn></table-wrap-foot></table-wrap><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Distribution of corramycin
MICs among 57 multidrug-resistant <italic>Escherichia coli</italic> clinical isolates. Corramycin is not affected
by aminoglycoside-modifying enzymes (AMEs), irrespective of the class
of AMEs. APH: aminoglycoside phosphotransferase; AAC: aminoglycoside
acetyltransferase; no.: number.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_0006" id="gr6" position="float"/></fig><p>Remarkably, one of the clinical isolates expressing
APH(3&#x02032;)-Ia
displayed resistance to corramycin (MIC &#x0003e; 64 &#x003bc;g mL<sup>&#x02013;1</sup>). Nevertheless, we can exclude the involvement of the phosphotransferase,
as corramycin maintained activity against other isolates expressing
the same APH variant. The majority of the tested isolates are multidrug-resistant
(<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">Table S9</ext-link>); thus, it appears likely that the loss
of susceptibility is caused by a distinct mechanism. To identify the
culprit of resistance, we carefully reassessed the genome of the isolate
with a particular focus on the <italic>sbmA</italic> gene. We have
previously described that mutations of SbmA, a transporter responsible
for the uptake of the antibiotic in <italic>E. coli</italic>, can
confer resistance to corramycin.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Strikingly,
we found a point mutation in the <italic>sbmA</italic> gene resulting
in a premature stop codon and, hence, a truncated protein. We further
assessed the susceptibility of the uptake-deficient strain in M9 minimal
medium and found that corramycin activity was restored with an MIC
of 1 &#x003bc;g mL<sup>&#x02013;1</sup>. This result supports our hypothesis
of SbmA inactivation being the root of resistance in <italic>E. coli</italic>, as corramycin uses an additional uptake system under minimal conditions
and does not solely rely on SbmA. We have previously demonstrated
that single SbmA mutations, despite conferring resistance <italic>in vitro</italic>, may not necessarily translate into a loss of efficacy <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> These findings, coupled
with the absence of cross-resistance to clinically used drugs, highlight
the potential of corramycin in overcoming drug resistance.</p></sec></sec><sec id="sec3"><title>Conclusion</title><p>The in-depth study of antibiotic self-resistance
mechanisms plays
a vital role in controlling the spread of AMR and its associated problems
for human health. This is especially true for compounds active against
Gram-negative bacteria, as infections caused by such pathogens are
generally more difficult to cure due to limited treatment options.
Novel antibiotics with innovative targets are needed. The development
of such is, however, time-consuming and expensive,<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> which makes the early, thorough understanding of resistance mechanisms
and their spread among pathogenic bacteria a very high priority.</p><p>Besides self-resistance mechanisms of tuberactinomycins,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> ComG is the first kinase within the APH enzyme
family able to modify and inactivate a peptidic antibiotic. Unlike
the capreomycin kinase Cph, however, ComG shows cofactor specificity
toward ATP and adopts a unique 3D-fold tailored toward corramycin
binding. It was particularly surprising to discover that corramycin
adopts a &#x003b2;-hairpin-like structure, which in turn allows the
part of the molecule that is modified by ComG to mimic a sugar. It
is unclear whether the active conformation of corramycin, or indeed
its solution structure, reflects that of corramycin bound to ComG.
Stabilization of the conformation observed in the ComG<sup>C</sup> crystal structure by six hydrogen bonds, combined with the presence
of the &#x003b1;-<italic>N</italic>-methylated phenylalanine at the
&#x003b2;-hairpin turn, may be sufficient to stabilize the conformation
in solution. The presence of a special &#x0201c;C&#x0201d;-shaped conformation
of capreomycin, which is also the result of intramolecular hydrogen
bonds, may hint at an evolutionary design for peptide antibiotics.
Corramycin appears to combine two very important areas of medicinal
chemistry in one molecule: &#x003b2;-hairpins and carbohydrate-mimetic
peptides. It may therefore serve as a valuable starting point for
future synthetic efforts to develop bioactive molecules featuring
either one or both elements.</p><p>The effect of corramycin phosphorylation
by ComG on target engagement
by the antibiotic remains elusive, but we view it as probable that,
analogously to aminoglycoside antibiotics, binding to the target is
abolished by phosphorylation. A potential mode of dephosphorylation
as activation mechanism has yet to be analyzed, but without a suitable
gene product in the corramycin BGC, it may either occur spontaneously
or, more likely, be the result of generic phosphatases. It remains
unclear whether phosphorylation is the main way by which the producing
strain protects itself against corramycin. We have previously hypothesized
that corramycin may be produced as a fatty acid-linked pro-drug that
is exported and subsequently hydrolyzed in the periplasm similar to
the description of the myxobacterial natural product vioprolide.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> Thus, ComG might only function as a highly efficient fail-safe in
case of a &#x0201c;production error&#x0201d; or unintentional import
of released corramycin, ultimately eliminating the need for a reactivation
mechanism.</p><p>Since phosphorylation is a very effective way to
neutralize antibiotics,
we performed genome mining studies to analyze the spread of potential
ComG homologues. The results were very promising in that the spread
is limited and mostly restricted to predicted biosynthetic gene clusters.
Critically, no presence on mobile genetic elements could be determined,
and our data indicate a rather narrow substrate range of ComG with
no activity detected on aminoglycosides, macrolides, fluoroquinolones,
and the peptide antibiotic capreomycin. We further characterized the
activity of corramycin against multidrug-resistant <italic>E. coli</italic> clinical isolates expressing different types of AMEs including common
aminoglycoside phosphotransferases. No cross-resistance was observed,
suggesting that the natural product is not part of the substrate range
of AMEs. To adapt the highly prevalent aminoglycoside phosphotransferases
for activity on corramycin would, among extensive mutations, also
require a specific C-terminal extension of these proteins. We are
of the opinion that such a process would likely be very slow, which,
in conjunction with its intriguing structure, the lack of cross-resistance
with commercially used antibiotics, and a most likely innovative target
renders corramycin a very promising antibiotic natural product primed
for further development.</p></sec></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/jacs.3c13208?goto=supporting-info">https://pubs.acs.org/doi/10.1021/jacs.3c13208</ext-link>.<list id="silist" list-type="simple"><list-item><p>Experimental details,
materials, and methods, as well
as supplementary figures and tables (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacs.3c13208/suppl_file/ja3c13208_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ja3c13208_si_001.pdf"><caption><p>ja3c13208_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="accession-codes" id="notes-5"><title>Accession Codes</title><p>Diffraction data
and refined structural models have been deposited in the PDB. See
Table S4 for PDB codes.</p></notes><notes notes-type="" id="notes-1"><title>Author Contributions</title><p><sup>&#x02021;</sup> S.A.,
F.F., and A.V.T. contributed equally to this paper. The manuscript
was written through contributions of all authors. All authors have
given approval to the final version of the manuscript.</p></notes><notes notes-type="funding-statement" id="notes-4"><p>This study was
supported by the German Centre for Infection Research (DZIF) in the
project &#x0201c;Development of corramycin as an antibiotic against
Gram-negative bacteria&#x0201d; (project: TTU 09.827, funding code:
8004809827) and the European Research Council (ERC CoG 101002326)
(to J.K.).</p></notes><notes notes-type="COI-statement" id="NOTES-d14e1091-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors would like to acknowledge David Auerbach for the
purification of the phosphorylated corramycin and Asfandyar Sikandar
for help with protein purification. In addition, the authors would
like to thank Kirsten Harmrolfs, who aided the structural elucidation
of Cor-P by NMR, and Natalia Kolesnik-Goldmann for shipment of the
clinical isolates. Furthermore, the authors would like to thank Norbert
Reiling and the National Reference Center for Mycobacteria (NRZ, Borstel,
Germany) for providing capreomyin.</p></ack><glossary id="dl1"><def-list><title>ABBREVIATIONS</title><def-item><term>GNAT</term><def><p>GCN5-related <italic>N</italic>-acetyltransferase</p></def></def-item><def-item><term>HMBC</term><def><p>heteronuclear
multiple bond correlation</p></def></def-item><def-item><term>RMSD</term><def><p>root mean square deviation</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Prestinaci</surname><given-names>F.</given-names></name>; <name><surname>Pezzotti</surname><given-names>P.</given-names></name>; <name><surname>Pantosti</surname><given-names>A.</given-names></name>
<article-title>Antimicrobial Resistance: A Global
Multifaceted Phenomenon</article-title>. <source>Pathog Glob Health</source>
<year>2015</year>, <volume>109</volume> (<issue>7</issue>), <fpage>309</fpage>&#x02013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1179/2047773215Y.0000000030</pub-id>.<pub-id pub-id-type="pmid">26343252</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><article-title>Antimicrobial Resistance: A Top Ten
Global Public Health Threat</article-title>. <source>eClinicalMedicine</source>
<year>2021</year>, <volume>41</volume>, <elocation-id>101221</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101221</pub-id>.<pub-id pub-id-type="pmid">34877512</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Pogue</surname><given-names>J. M.</given-names></name>; <name><surname>Kaye</surname><given-names>K. S.</given-names></name>; <name><surname>Cohen</surname><given-names>D. A.</given-names></name>; <name><surname>Marchaim</surname><given-names>D.</given-names></name>
<article-title>Appropriate Antimicrobial
Therapy in the Era of Multidrug-Resistant Human Pathogens</article-title>. <source>Clin Microbiol Infect</source>
<year>2015</year>, <volume>21</volume> (<issue>4</issue>), <fpage>302</fpage>&#x02013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2014.12.025</pub-id>.<pub-id pub-id-type="pmid">25743999</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Pendleton</surname><given-names>J. N.</given-names></name>; <name><surname>Gorman</surname><given-names>S. P.</given-names></name>; <name><surname>Gilmore</surname><given-names>B. F.</given-names></name>
<article-title>Clinical
Relevance of the ESKAPE
Pathogens</article-title>. <source>Expert Review of Anti-infective Therapy</source>
<year>2013</year>, <volume>11</volume> (<issue>3</issue>), <fpage>297</fpage>&#x02013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1586/eri.13.12</pub-id>.<pub-id pub-id-type="pmid">23458769</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Impey</surname><given-names>R. E.</given-names></name>; <name><surname>Hawkins</surname><given-names>D. A.</given-names></name>; <name><surname>Sutton</surname><given-names>J. M.</given-names></name>; <name><surname>Soares da Costa</surname><given-names>T. P.</given-names></name>
<article-title>Overcoming
Intrinsic and Acquired Resistance Mechanisms Associated with the Cell
Wall of Gram-Negative Bacteria</article-title>. <source>Antibiotics
(Basel)</source>
<year>2020</year>, <volume>9</volume> (<issue>9</issue>), <fpage>623</fpage><pub-id pub-id-type="doi">10.3390/antibiotics9090623</pub-id>.<pub-id pub-id-type="pmid">32961699</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Pandeya</surname><given-names>A.</given-names></name>; <name><surname>Ojo</surname><given-names>I.</given-names></name>; <name><surname>Alegun</surname><given-names>O.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>
<article-title>Periplasmic Targets for the Development
of Effective Antimicrobials against Gram-Negative Bacteria</article-title>. <source>ACS Infect. Dis.</source>
<year>2020</year>, <volume>6</volume> (<issue>9</issue>), <fpage>2337</fpage>&#x02013;<lpage>2354</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00384</pub-id>.<pub-id pub-id-type="pmid">32786281</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Herrmann</surname><given-names>J.</given-names></name>; <name><surname>Fayad</surname><given-names>A. A.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<article-title>Natural Products
from Myxobacteria:
Novel Metabolites and Bioactivities</article-title>. <source>Nat. Prod.
Rep.</source>
<year>2017</year>, <volume>34</volume> (<issue>2</issue>), <fpage>135</fpage>&#x02013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1039/C6NP00106H</pub-id>.<pub-id pub-id-type="pmid">27907217</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Couturier</surname><given-names>C.</given-names></name>; <name><surname>Gro&#x000df;</surname><given-names>S.</given-names></name>; <name><surname>von Tesmar</surname><given-names>A.</given-names></name>; <name><surname>Hoffmann</surname><given-names>J.</given-names></name>; <name><surname>Deckarm</surname><given-names>S.</given-names></name>; <name><surname>Fievet</surname><given-names>A.</given-names></name>; <name><surname>Dubarry</surname><given-names>N.</given-names></name>; <name><surname>Taillier</surname><given-names>T.</given-names></name>; <name><surname>P&#x000f6;verlein</surname><given-names>C.</given-names></name>; <name><surname>Stump</surname><given-names>H.</given-names></name>; <name><surname>Kurz</surname><given-names>M.</given-names></name>; <name><surname>Toti</surname><given-names>L.</given-names></name>; <name><surname>Haag Richter</surname><given-names>S.</given-names></name>; <name><surname>Schummer</surname><given-names>D.</given-names></name>; <name><surname>Sizun</surname><given-names>P.</given-names></name>; <name><surname>Hoffmann</surname><given-names>M.</given-names></name>; <name><surname>Prasad Awal</surname><given-names>R.</given-names></name>; <name><surname>Zaburannyi</surname><given-names>N.</given-names></name>; <name><surname>Harmrolfs</surname><given-names>K.</given-names></name>; <name><surname>Wink</surname><given-names>J.</given-names></name>; <name><surname>Lessoud</surname><given-names>E.</given-names></name>; <name><surname>Vermat</surname><given-names>T.</given-names></name>; <name><surname>Cazals</surname><given-names>V.</given-names></name>; <name><surname>Silve</surname><given-names>S.</given-names></name>; <name><surname>Bauer</surname><given-names>A.</given-names></name>; <name><surname>Mourez</surname><given-names>M.</given-names></name>; <name><surname>Fraisse</surname><given-names>L.</given-names></name>; <name><surname>Leroi-Geissler</surname><given-names>C.</given-names></name>; <name><surname>Rey</surname><given-names>A.</given-names></name>; <name><surname>Versluys</surname><given-names>S.</given-names></name>; <name><surname>Bacqu&#x000e9;</surname><given-names>E.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>; <name><surname>Renard</surname><given-names>S.</given-names></name>
<article-title>Structure Elucidation, Total Synthesis, Antibacterial
In Vivo Efficacy and Biosynthesis Proposal of Myxobacterial Corramycin</article-title>. <source>Angew. Chem., Int. Ed. Engl.</source>
<year>2022</year>, <volume>61</volume> (<issue>51</issue>), <elocation-id>e202210747</elocation-id><pub-id pub-id-type="doi">10.1002/anie.202210747</pub-id>.<pub-id pub-id-type="pmid">36197755</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Renard</surname><given-names>S.</given-names></name>; <name><surname>Versluys</surname><given-names>S.</given-names></name>; <name><surname>Taillier</surname><given-names>T.</given-names></name>; <name><surname>Dubarry</surname><given-names>N.</given-names></name>; <name><surname>Leroi-Geissler</surname><given-names>C.</given-names></name>; <name><surname>Rey</surname><given-names>A.</given-names></name>; <name><surname>Cornaire</surname><given-names>E.</given-names></name>; <name><surname>Sordello</surname><given-names>S.</given-names></name>; <name><surname>Carry</surname><given-names>J.-C. B.</given-names></name>; <name><surname>Angouillant-Boniface</surname><given-names>O.</given-names></name>; <name><surname>Gouyon</surname><given-names>T.</given-names></name>; <name><surname>Thompson</surname><given-names>F.</given-names></name>; <name><surname>Lebourg</surname><given-names>G.</given-names></name>; <name><surname>Certal</surname><given-names>V.</given-names></name>; <name><surname>Balazs</surname><given-names>L.</given-names></name>; <name><surname>Arranz</surname><given-names>E.</given-names></name>; <name><surname>Doerflinger</surname><given-names>G.</given-names></name>; <name><surname>Bretin</surname><given-names>F.</given-names></name>; <name><surname>Gervat</surname><given-names>V.</given-names></name>; <name><surname>Brohan</surname><given-names>E.</given-names></name>; <name><surname>Kraft</surname><given-names>V.</given-names></name>; <name><surname>Boulenc</surname><given-names>X.</given-names></name>; <name><surname>Ducelier</surname><given-names>C.</given-names></name>; <name><surname>Bacqu&#x000e9;</surname><given-names>E.</given-names></name>; <name><surname>Couturier</surname><given-names>C.</given-names></name>
<article-title>Optimization of the Antibacterial Spectrum and the
Developability Profile of the Novel-Class Natural Product Corramycin</article-title>. <source>J. Med. Chem.</source>
<year>2023</year>, <volume>66</volume> (<issue>24</issue>), <fpage>16869</fpage>&#x02013;<lpage>16887</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c01564</pub-id>.<pub-id pub-id-type="pmid">38088830</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Tracanna</surname><given-names>V.</given-names></name>; <name><surname>de Jong</surname><given-names>A.</given-names></name>; <name><surname>Medema</surname><given-names>M. H.</given-names></name>; <name><surname>Kuipers</surname><given-names>O. P.</given-names></name>
<article-title>Mining Prokaryotes
for Antimicrobial Compounds: From Diversity to Function</article-title>. <source>FEMS Microbiology Reviews</source>
<year>2017</year>, <volume>41</volume> (<issue>3</issue>), <fpage>417</fpage>&#x02013;<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fux014</pub-id>.<pub-id pub-id-type="pmid">28402441</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Panter</surname><given-names>F.</given-names></name>; <name><surname>Krug</surname><given-names>D.</given-names></name>; <name><surname>Baumann</surname><given-names>S.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<article-title>Self-Resistance
Guided Genome Mining Uncovers New Topoisomerase Inhibitors from Myxobacteria</article-title>. <source>Chem. Sci.</source>
<year>2018</year>, <volume>9</volume> (<issue>21</issue>), <fpage>4898</fpage>&#x02013;<lpage>4908</lpage>. <pub-id pub-id-type="doi">10.1039/C8SC01325J</pub-id>.<pub-id pub-id-type="pmid">29910943</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Almabruk</surname><given-names>K. H.</given-names></name>; <name><surname>Dinh</surname><given-names>L. K.</given-names></name>; <name><surname>Philmus</surname><given-names>B.</given-names></name>
<article-title>Self-Resistance
of Natural Product
Producers: Past, Present, and Future Focusing on Self-Resistant Protein
Variants</article-title>. <source>ACS Chem. Biol.</source>
<year>2018</year>, <volume>13</volume> (<issue>6</issue>), <fpage>1426</fpage>&#x02013;<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.8b00173</pub-id>.<pub-id pub-id-type="pmid">29763292</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Li</surname><given-names>X.-Z.</given-names></name>; <name><surname>Nikaido</surname><given-names>H.</given-names></name>
<article-title>Efflux-Mediated Drug
Resistance in Bacteria: An Update</article-title>. <source>Drugs</source>
<year>2009</year>, <volume>69</volume> (<issue>12</issue>), <fpage>1555</fpage>&#x02013;<lpage>1623</lpage>. <pub-id pub-id-type="doi">10.2165/11317030-000000000-00000</pub-id>.<pub-id pub-id-type="pmid">19678712</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Smith</surname><given-names>C. A.</given-names></name>; <name><surname>Baker</surname><given-names>E. N.</given-names></name>
<article-title>Aminoglycoside Antibiotic Resistance by Enzymatic Deactivation</article-title>. <source>CDTID</source>
<year>2002</year>, <volume>2</volume> (<issue>2</issue>), <fpage>143</fpage>&#x02013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.2174/1568005023342533</pub-id>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Wright</surname><given-names>G. D.</given-names></name>
<article-title>Aminoglycoside
Phosphotransferases: Proteins, Structure, and Mechanism</article-title>. <source>Front Biosci</source>
<year>1999</year>, <volume>4</volume> (<issue>1&#x02013;3</issue>), <fpage>d9</fpage><pub-id pub-id-type="doi">10.2741/Wright</pub-id>.<pub-id pub-id-type="pmid">9872733</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><person-group person-group-type="allauthors"><name><surname>Shi</surname><given-names>K.</given-names></name>; <name><surname>Caldwell</surname><given-names>S. J.</given-names></name>; <name><surname>Fong</surname><given-names>D. H.</given-names></name>; <name><surname>Berghuis</surname><given-names>A. M.</given-names></name></person-group><article-title>Prospects for
Circumventing Aminoglycoside Kinase Mediated Antibiotic Resistance</article-title>. <source>Front. Cell. Infect. Microbiol.</source><year>2013</year>, <volume>3</volume>,<pub-id pub-id-type="doi">10.3389/fcimb.2013.00022</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Pan</surname><given-names>Y.-C.</given-names></name>; <name><surname>Wang</surname><given-names>Y.-L.</given-names></name>; <name><surname>Toh</surname><given-names>S.-I.</given-names></name>; <name><surname>Hsu</surname><given-names>N.-S.</given-names></name>; <name><surname>Lin</surname><given-names>K.-H.</given-names></name>; <name><surname>Xu</surname><given-names>Z.</given-names></name>; <name><surname>Huang</surname><given-names>S.-C.</given-names></name>; <name><surname>Wu</surname><given-names>T.-K.</given-names></name>; <name><surname>Li</surname><given-names>T.-L.</given-names></name>; <name><surname>Chang</surname><given-names>C.-Y.</given-names></name>
<article-title>Dual-Mechanism
Confers Self-Resistance to the Antituberculosis Antibiotic Capreomycin</article-title>. <source>ACS Chem. Biol.</source>
<year>2022</year>, <volume>17</volume> (<issue>1</issue>), <fpage>138</fpage>&#x02013;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.1c00799</pub-id>.<pub-id pub-id-type="pmid">34994196</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Barkei</surname><given-names>J. J.</given-names></name>; <name><surname>Kevany</surname><given-names>B. M.</given-names></name>; <name><surname>Felnagle</surname><given-names>E. A.</given-names></name>; <name><surname>Thomas</surname><given-names>M. G.</given-names></name>
<article-title>Investigations into
Viomycin Biosynthesis by Using Heterologous Production in Streptomyces
Lividans</article-title>. <source>Chembiochem</source>
<year>2009</year>, <volume>10</volume> (<issue>2</issue>), <fpage>366</fpage>&#x02013;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.200800646</pub-id>.<pub-id pub-id-type="pmid">19105177</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Robicsek</surname><given-names>A.</given-names></name>; <name><surname>Strahilevitz</surname><given-names>J.</given-names></name>; <name><surname>Jacoby</surname><given-names>G. A.</given-names></name>; <name><surname>Macielag</surname><given-names>M.</given-names></name>; <name><surname>Abbanat</surname><given-names>D.</given-names></name>; <name><surname>Hye Park</surname><given-names>C.</given-names></name>; <name><surname>Bush</surname><given-names>K.</given-names></name>; <name><surname>Hooper</surname><given-names>D. C.</given-names></name>
<article-title>Fluoroquinolone-Modifying
Enzyme: A New Adaptation of a Common Aminoglycoside Acetyltransferase</article-title>. <source>Nat. Med.</source>
<year>2006</year>, <volume>12</volume> (<issue>1</issue>), <fpage>83</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1038/nm1347</pub-id>.<pub-id pub-id-type="pmid">16369542</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Vetting</surname><given-names>M. W.</given-names></name>; <name><surname>Park</surname><given-names>C. H.</given-names></name>; <name><surname>Hegde</surname><given-names>S. S.</given-names></name>; <name><surname>Jacoby</surname><given-names>G. A.</given-names></name>; <name><surname>Hooper</surname><given-names>D. C.</given-names></name>; <name><surname>Blanchard</surname><given-names>J. S.</given-names></name>
<article-title>Mechanistic and Structural Analysis of Aminoglycoside
N-Acetyltransferase AAC(6&#x02032;)-Ib and Its Bifunctional, Fluoroquinolone-Active
AAC(6&#x02032;)-Ib-Cr Variant</article-title>. <source>Biochemistry</source>
<year>2008</year>, <volume>47</volume> (<issue>37</issue>), <fpage>9825</fpage>&#x02013;<lpage>9835</lpage>. <pub-id pub-id-type="doi">10.1021/bi800664x</pub-id>.<pub-id pub-id-type="pmid">18710261</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Putignano</surname><given-names>V.</given-names></name>; <name><surname>Rosato</surname><given-names>A.</given-names></name>; <name><surname>Banci</surname><given-names>L.</given-names></name>; <name><surname>Andreini</surname><given-names>C.</given-names></name>
<article-title>MetalPDB in 2018: A
Database of Metal Sites in Biological Macromolecular Structures</article-title>. <source>Nucleic Acids Res.</source>
<year>2018</year>, <volume>46</volume> (<issue>D1</issue>), <fpage>D459</fpage>&#x02013;<lpage>D464</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx989</pub-id>.<pub-id pub-id-type="pmid">29077942</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Caldwell</surname><given-names>S. J.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Berghuis</surname><given-names>A. M.</given-names></name>
<article-title>Antibiotic
Binding Drives Catalytic
Activation of Aminoglycoside Kinase APH(2&#x02033;)-Ia</article-title>. <source>Structure</source>
<year>2016</year>, <volume>24</volume> (<issue>6</issue>), <fpage>935</fpage>&#x02013;<lpage>945</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2016.04.002</pub-id>.<pub-id pub-id-type="pmid">27161980</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Alcock</surname><given-names>B. P.</given-names></name>; <name><surname>Huynh</surname><given-names>W.</given-names></name>; <name><surname>Chalil</surname><given-names>R.</given-names></name>; <name><surname>Smith</surname><given-names>K. W.</given-names></name>; <name><surname>Raphenya</surname><given-names>A. R.</given-names></name>; <name><surname>Wlodarski</surname><given-names>M. A.</given-names></name>; <name><surname>Edalatmand</surname><given-names>A.</given-names></name>; <name><surname>Petkau</surname><given-names>A.</given-names></name>; <name><surname>Syed</surname><given-names>S. A.</given-names></name>; <name><surname>Tsang</surname><given-names>K. K.</given-names></name>; <name><surname>Baker</surname><given-names>S. J. C.</given-names></name>; <name><surname>Dave</surname><given-names>M.</given-names></name>; <name><surname>McCarthy</surname><given-names>M. C.</given-names></name>; <name><surname>Mukiri</surname><given-names>K. M.</given-names></name>; <name><surname>Nasir</surname><given-names>J. A.</given-names></name>; <name><surname>Golbon</surname><given-names>B.</given-names></name>; <name><surname>Imtiaz</surname><given-names>H.</given-names></name>; <name><surname>Jiang</surname><given-names>X.</given-names></name>; <name><surname>Kaur</surname><given-names>K.</given-names></name>; <name><surname>Kwong</surname><given-names>M.</given-names></name>; <name><surname>Liang</surname><given-names>Z. C.</given-names></name>; <name><surname>Niu</surname><given-names>K. C.</given-names></name>; <name><surname>Shan</surname><given-names>P.</given-names></name>; <name><surname>Yang</surname><given-names>J. Y. J.</given-names></name>; <name><surname>Gray</surname><given-names>K. L.</given-names></name>; <name><surname>Hoad</surname><given-names>G. R.</given-names></name>; <name><surname>Jia</surname><given-names>B.</given-names></name>; <name><surname>Bhando</surname><given-names>T.</given-names></name>; <name><surname>Carfrae</surname><given-names>L. A.</given-names></name>; <name><surname>Farha</surname><given-names>M. A.</given-names></name>; <name><surname>French</surname><given-names>S.</given-names></name>; <name><surname>Gordzevich</surname><given-names>R.</given-names></name>; <name><surname>Rachwalski</surname><given-names>K.</given-names></name>; <name><surname>Tu</surname><given-names>M. M.</given-names></name>; <name><surname>Bordeleau</surname><given-names>E.</given-names></name>; <name><surname>Dooley</surname><given-names>D.</given-names></name>; <name><surname>Griffiths</surname><given-names>E.</given-names></name>; <name><surname>Zubyk</surname><given-names>H. L.</given-names></name>; <name><surname>Brown</surname><given-names>E. D.</given-names></name>; <name><surname>Maguire</surname><given-names>F.</given-names></name>; <name><surname>Beiko</surname><given-names>R. G.</given-names></name>; <name><surname>Hsiao</surname><given-names>W. W. L.</given-names></name>; <name><surname>Brinkman</surname><given-names>F. S. L.</given-names></name>; <name><surname>Van Domselaar</surname><given-names>G.</given-names></name>; <name><surname>McArthur</surname><given-names>A. G.</given-names></name>
<article-title>CARD 2023: Expanded
Curation, Support for Machine Learning, and Resistome Prediction at
the Comprehensive Antibiotic Resistance Database</article-title>. <source>Nucleic Acids Res.</source>
<year>2023</year>, <volume>51</volume> (<issue>D1</issue>), <fpage>D690</fpage>&#x02013;<lpage>D699</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac920</pub-id>.<pub-id pub-id-type="pmid">36263822</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Mancini</surname><given-names>S.</given-names></name>; <name><surname>Marchesi</surname><given-names>M.</given-names></name>; <name><surname>Imkamp</surname><given-names>F.</given-names></name>; <name><surname>Wagner</surname><given-names>K.</given-names></name>; <name><surname>Keller</surname><given-names>P. M.</given-names></name>; <name><surname>Quiblier</surname><given-names>C.</given-names></name>; <name><surname>Bodendoerfer</surname><given-names>E.</given-names></name>; <name><surname>Courvalin</surname><given-names>P.</given-names></name>; <name><surname>B&#x000f6;ttger</surname><given-names>E. C.</given-names></name>
<article-title>Population-Based Inference of Aminoglycoside
Resistance
Mechanisms in Escherichia Coli</article-title>. <source>EBioMedicine</source>
<year>2019</year>, <volume>46</volume>, <fpage>184</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.07.020</pub-id>.<pub-id pub-id-type="pmid">31307955</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="weblink" id="cit25"><source>The European Committee on Antimicrobial Susceptibility
Testing. Breakpoint
tables for interpretation of MICs and zone diameters. Version 14.0,
2024</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.eucast.org/clinical_breakpoints">https://www.eucast.org/clinical_breakpoints</uri> (accessed 2024&#x02013;01&#x02013;08).</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Miethke</surname><given-names>M.</given-names></name>; <name><surname>Pieroni</surname><given-names>M.</given-names></name>; <name><surname>Weber</surname><given-names>T.</given-names></name>; <name><surname>Br&#x000f6;nstrup</surname><given-names>M.</given-names></name>; <name><surname>Hammann</surname><given-names>P.</given-names></name>; <name><surname>Halby</surname><given-names>L.</given-names></name>; <name><surname>Arimondo</surname><given-names>P. B.</given-names></name>; <name><surname>Glaser</surname><given-names>P.</given-names></name>; <name><surname>Aigle</surname><given-names>B.</given-names></name>; <name><surname>Bode</surname><given-names>H. B.</given-names></name>; <name><surname>Moreira</surname><given-names>R.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Luzhetskyy</surname><given-names>A.</given-names></name>; <name><surname>Medema</surname><given-names>M. H.</given-names></name>; <name><surname>Pernodet</surname><given-names>J.-L.</given-names></name>; <name><surname>Stadler</surname><given-names>M.</given-names></name>; <name><surname>Tormo</surname><given-names>J. R.</given-names></name>; <name><surname>Genilloud</surname><given-names>O.</given-names></name>; <name><surname>Truman</surname><given-names>A. W.</given-names></name>; <name><surname>Weissman</surname><given-names>K. J.</given-names></name>; <name><surname>Takano</surname><given-names>E.</given-names></name>; <name><surname>Sabatini</surname><given-names>S.</given-names></name>; <name><surname>Stegmann</surname><given-names>E.</given-names></name>; <name><surname>Br&#x000f6;tz-Oesterhelt</surname><given-names>H.</given-names></name>; <name><surname>Wohlleben</surname><given-names>W.</given-names></name>; <name><surname>Seemann</surname><given-names>M.</given-names></name>; <name><surname>Empting</surname><given-names>M.</given-names></name>; <name><surname>Hirsch</surname><given-names>A. K. H.</given-names></name>; <name><surname>Loretz</surname><given-names>B.</given-names></name>; <name><surname>Lehr</surname><given-names>C.-M.</given-names></name>; <name><surname>Titz</surname><given-names>A.</given-names></name>; <name><surname>Herrmann</surname><given-names>J.</given-names></name>; <name><surname>Jaeger</surname><given-names>T.</given-names></name>; <name><surname>Alt</surname><given-names>S.</given-names></name>; <name><surname>Hesterkamp</surname><given-names>T.</given-names></name>; <name><surname>Winterhalter</surname><given-names>M.</given-names></name>; <name><surname>Schiefer</surname><given-names>A.</given-names></name>; <name><surname>Pfarr</surname><given-names>K.</given-names></name>; <name><surname>Hoerauf</surname><given-names>A.</given-names></name>; <name><surname>Graz</surname><given-names>H.</given-names></name>; <name><surname>Graz</surname><given-names>M.</given-names></name>; <name><surname>Lindvall</surname><given-names>M.</given-names></name>; <name><surname>Ramurthy</surname><given-names>S.</given-names></name>; <name><surname>Karl&#x000e9;n</surname><given-names>A.</given-names></name>; <name><surname>van Dongen</surname><given-names>M.</given-names></name>; <name><surname>Petkovic</surname><given-names>H.</given-names></name>; <name><surname>Keller</surname><given-names>A.</given-names></name>; <name><surname>Peyrane</surname><given-names>F.</given-names></name>; <name><surname>Donadio</surname><given-names>S.</given-names></name>; <name><surname>Fraisse</surname><given-names>L.</given-names></name>; <name><surname>Piddock</surname><given-names>L. J. V.</given-names></name>; <name><surname>Gilbert</surname><given-names>I. H.</given-names></name>; <name><surname>Moser</surname><given-names>H. E.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<article-title>Towards the
Sustainable Discovery and Development of New Antibiotics</article-title>. <source>Nat. Rev. Chem.</source>
<year>2021</year>, <volume>5</volume> (<issue>10</issue>), <fpage>726</fpage>&#x02013;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1038/s41570-021-00313-1</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Walesch</surname><given-names>S.</given-names></name>; <name><surname>Birkelbach</surname><given-names>J.</given-names></name>; <name><surname>J&#x000e9;z&#x000e9;quel</surname><given-names>G.</given-names></name>; <name><surname>Haeckl</surname><given-names>F. P. J.</given-names></name>; <name><surname>Hegemann</surname><given-names>J. D.</given-names></name>; <name><surname>Hesterkamp</surname><given-names>T.</given-names></name>; <name><surname>Hirsch</surname><given-names>A. K. H.</given-names></name>; <name><surname>Hammann</surname><given-names>P.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<article-title>Fighting Antibiotic
Resistance&#x02014;Strategies and
(Pre)Clinical Developments to Find New Antibacterials</article-title>. <source>EMBO Reports</source>
<year>2023</year>, <volume>24</volume> (<issue>1</issue>), <elocation-id>e56033</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202256033</pub-id>.<pub-id pub-id-type="pmid">36533629</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Yan</surname><given-names>F.</given-names></name>; <name><surname>Auerbach</surname><given-names>D.</given-names></name>; <name><surname>Chai</surname><given-names>Y.</given-names></name>; <name><surname>Keller</surname><given-names>L.</given-names></name>; <name><surname>Tu</surname><given-names>Q.</given-names></name>; <name><surname>H&#x000fc;ttel</surname><given-names>S.</given-names></name>; <name><surname>Glemser</surname><given-names>A.</given-names></name>; <name><surname>Grab</surname><given-names>H. A.</given-names></name>; <name><surname>Bach</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<article-title>Biosynthesis and Heterologous Production
of Vioprolides: Rational Biosynthetic Engineering and Unprecedented
4-Methylazetidinecarboxylic Acid Formation</article-title>. <source>Angew. Chem. Int. Ed</source>
<year>2018</year>, <volume>57</volume> (<issue>28</issue>), <fpage>8754</fpage>&#x02013;<lpage>8759</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201802479</pub-id>.</mixed-citation></ref></ref-list></back></article>